Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 3 February 2023, including: Amgen, Inc. launches first US biosimilar to Humira; strong launches set to help Bristol Myers Squibb Company as it faces losses of exclusivity; Eisai Co., Ltd. preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch" - Scrip, 31 Jan, 2023.)
(Also see "Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond" - Scrip, 30 Jan, 2023.)
(Also see "Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer’s Drug Leqembi" - Scrip, 27 Jan, 2023.)
(Also see "10 Clinical Trials To Watch Out For In 2023" - Scrip, 26 Jan, 2023.)
(Also see "Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances" - Scrip, 27 Jan, 2023.)